RBC Capital downgraded Avid Bioservices (CDMO) to Sector Perform from Outperform with a price target of $12.50, up from $12, after the company announced an agreement to be acquired by GHO Capital Partners and Ampersand Capital Partners for $12.50 per share. RBC expects the transaction to close at this price.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.